检索结果-南通市图书馆

Non-alcoholic fatty liver disease-related hepatocellular carcinoma:Is there a role for immunotherapy?

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2022年第28期28卷 3595-3607页

作者： Ângelo Z Mattos Jose D Debes arndt vogel Marco Arrese Xavier Revelo Tales Henrique S Pase Muriel Manica Angelo A Mattos Graduate Program in Medicine:Hepatology Federal University of Health Sciences of Porto AlegrePorto Alegre 90050-170Brazil Gastroenterology and Hepatology Unit Irmandade Santa Casa de Misericórdia de Porto AlegrePorto Alegre 90050-170Brazil Department of Medicine University of MinnesotaMinneapolisMN 55455United States Department of Gastroenterology and Hepatology Erasmus Medical CenterRotterdam 999025Netherlands Department of Gastroenterology Hepatology and EndocrinologyHannover Medical SchoolHannover 30625Germany Department of Gastroenterology School of Medicine and Center for Aging and RegenerationFaculty of Biological SciencesPontificia Universidad Católica de ChileSantiago 3580000Chile Department of Integrative Biology and Physiology University of MinnesotaMinneapolisMN 55455United States Internal Medicine Unit Irmandade Santa Casa de Misericórdia de Porto AlegrePorto Alegre 90020-090Brazil

Hepatocellular carcinoma(HCC)is among the most common cancers and it is a major cause of cancer-related ***-alcoholic fatty liver disease(NAFLD)affects approximately one fourth of individuals worldwide and it is becoming one of the most important causes of *** pathogenic mechanisms leading to NAFLD-related HCC are complex and not completely ***,metabolic,fibrogenic,oncogenic,inflammatory and immunological pathways seem to be ***-line therapy of advanced HCC has recently undergone major changes,since the combination of atezolizumab and bevacizumab was proven to increase survival when compared to *** immune-oncology drugs are also demonstrating promising results in patients with advanced HCC when compared to traditional systemic ***,initial studies raised concerns that the advantages of immunotherapy might depend on the underlying liver disease,which seems to be particularly important in NAFLD-related HCC,as these tumors might not benefit from *** article will review the mechanisms of NAFLD-related hepatocarcinogenesis,with an emphasis on its immune aspects,the efficacy of traditional systemic therapy for advanced NAFLD-related HCC,and the most recent data on the role of immunotherapy for this specific group of patients,showing that the management of this condition should be individualized and that a general recommendation cannot be made at this time.

关键词： Non-alcoholic fatty liver disease Hepatocellular carcinoma Hepatocarcinogenesis Immunology Immunotherapy Tyrosine kinase inhibitors

Immune aspects of hepatocellular carcinoma:From immune markers for early detection to immunotherapy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal Oncology 2021年第9期13卷 1132-1143页

作者： Ângelo Z Mattos Jose D Debes Andre Boonstra arndt vogel Angelo A Mattos Graduate Program in Medicine:Hepatology Federal University of Health Sciences of Porto AlegrePorto Alegre 90050-170Brazil Gastroenterology and Hepatology Unit Irmandade Santa Casa de Misericórdia de Porto AlegrePorto Alegre 90020-090Brazil Department of Medicine Division of Gastroenterology and Infectious DiseasesUniversity of MinnesotaMinneapolisMN 55812United States Department of Gastroenterology and Hepatology Erasmus Medical CenterRotterdam NL-3015The Netherlands Department of Gastroenterology Hepatology and EndocrinologyHannover Medical SchoolHannover 30625Germany

Hepatocellular carcinoma(HCC)is one of the most prevalent cancers and one of the main causes of cancer-related deaths *** HCCs develop in an inflammatory microenvironment,and mounting evidence emphasizes the importance of immune aspects in *** normal physiology,both innate and adaptive immune responses are responsible for eliminating malignantly transformed cells,thus preventing the development of liver ***,in the setting of impaired natural killer cells and exhaustion of T cells,HCC can *** immunogenic features of HCC have relevant clinical *** is a large number of immune markers currently being studied for the early detection of liver cancer,which would be critical in order to improve surveillance ***,novel immunotherapies have recently been proven to be effective,and the combination of atezolizumab and bevacizumab is currently the most effective treatment for advanced *** is expected that in the near future different subgroups of patients will benefit from specific *** better we understand the immune aspects of HCC,the greater the benefit to patients through surveillance aiming for early detection of liver cancer,which allows for curative treatments,and,in cases of advanced disease,through the selection of the best possible therapy for each individual.

关键词： Hepatocellular carcinoma Immunology Hepatocarcinogenesis Surveillance Biomarker Immunotherapy

hsa-mir-183 is frequently methylated and related to poor survival in human hepatocellular carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2017年第9期23卷 1568-1575页

作者： Sumadi Lukman Anwar Till Krech Britta Hasemeier Elisa Schipper Nora Schweitzer arndt vogel Hans Kreipe Reena Buurman Britta Skawran Ulrich Lehmann Ulrich Lehmann Institute of PathologyMedizinische Hochschule Hannover Department of Surgery Faculty of Medicine Universitas Gadjah Mada Department of Gastroenterology Hepatology and EndocrinologyMedizinische Hochschule Hannover Institute of Human Genetics Medizinische Hochschule Hannover

AIM To screen clinically relevant micro RNAs (mi RNAs) silenced by DNA methylation in human hepatocellular carcinoma(HCC).METHODS Knockdown of DNA methyltransferases (DNMTs) using si RNAs and mi RNA profiling in HCC cell lines were performed to identify DNA hypermethylation-mediated mi RNA downregulation. Confirmation using individual quantitative real-time PCR (qR T-PCR) assays was thenperformed followed by DNA methylation quantification at the promoter of the mi RNA genes. Quantification of DNA methylation and mi RNA expression was then performed in primary HCC tumor samples and related with clinicopathological *** mi RNA profiling after DNMT knockdown in HCC cell lines revealed upregulation of mi R-23, mi R-25 and mi R-183. After q RT-PCR confirmation and Cp G island methylation quantification of these miR NAs in cell lines, further analysis in primary HCC specimens showed that hsa-mi R-183 is hypermethylated in 30% of HCC (n = 40). Expression of mature miR-183 showed an inverse correlation with DNA methylation levels. In HCC cells, DNMT knockdown and 5-aza-2'-deoxycytidine treatment reduced methylation and stimulated expression of mi R-183. In HCC patients, hypermethylation at hsami R-183 promoter significantly correlates with poor survival (log-rank test P = 0.03). DNA methylation analysis in healthy liver, benign liver tumors (hepatocellular adenoma and focal nodular hyperplasia) and their corresponding adjacent tissues showed absence of hypermethylation supporting the notion that aberrant methylation at hsa-miR-183 is specific for the malignant transformation of *** Our data indicate that hypermethylation of hsa-miR-183 is a frequent event in HCC and potentially useful as a novel surrogate diagnostic and prognostic marker.

关键词： hsa-miR-183 DNA methylation DNMT 击倒 microRNA microarray

Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal Oncology 2023年第11期15卷 1900-1912页

作者： Sirish Dharmapuri UmutÖzbek Hiren Jethra Tomi Jun Thomas U Marron Anwaar Saeed Yi-Hsiang Huang Mahvish Muzaffar Matthias Pinter Lorenz Balcar Claudia Fulgenzi Suneetha Amara arndt Weinmann Nicola Personeni Bernhard Scheiner Tiziana Pressiani Musharraf Navaid Bertram Bengsch Sonal Paul Uqba Khan Dominik Bettinger Naoshi Nishida Yehia Ibrahim Mohamed arndt vogel Anuhya Gampa James Korolewicz Antonella Cammarota Ahmed Kaseb Peter R Galle Anjana Pillai Ying-Hong Wan Alessio Cortellini Masatoshi Kudo Antonio D’Alessio Lorenza Rimassa David James Pinato Celina Ang Tisch Cancer Institute Icahn School of Medicine at Mount SinaiNew YorkNY 10029United States Department of Population Health Science and Policy Icahn School of Medicine at Mount SinaiNew YorkNY 10029United States Department of Data Analytics Harrisburg Harrisburg University of Science and TechnologyHarrisburdPA 17101United States SEMA4 StamfordCT 06902United States Division of Medical Oncology Kansas University of Kansas Cancer CenterKansasMO 66160United States Division of Gastroenterology and Hepatology Taipei Veterans General HospitalTaipei 11217Taiwan Department of Internal Medicine Brody School of MedicineEast Carolina UniversityGreenvilleNC 27858United States Department of Internal Medicine III Division of Gastroenterology and HepatologyMedical University of ViennaVienna 1090Austria Department of Surgery and Cancer Imperial College LondonHammersmith Hospital LondonLondon W120HSUnited Kingdom Department of Hepatology Johannes Gutenberg-University Medical CentreNiedersachsen 30625Germany Medical Oncology Unit ASST GardaVia Lungomella ValsecchiBresciaManerbio 25025Italy Medical Oncology and Hematology Unit Humanitas Cancer CenterIRCCS Humanitas Research HospitalMilanRozzano 20089Italy Department of Medicine II Univ Med Ctr FreiburgHugstetter Str 55University Hospital FreiburgFreiburg D-79106Germany Department of Oncology Baltimore LifeBridge HealthBaltimoreMD 21215United States Division of Hematology and Oncology Weill Cornell Medical CollegeNY 10065United States Department of Gastroenterology and Hepatology Kindai University Faculty of MedicineOsaka 577-8502Japan Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer CenterHoustonTX 77030United States Department of Gastroenterology Hepatology and Endocrinology HannoverArndt VogelMedical School HannoverCarl-Neubergstr.Hannover 30659Germany Department of Hepatology Rush University Medical Group 1725 W Harrison St Ste 158ChicagoIL 60612United States Department of Biomedica

BACKGROUND A well-recognized class effect of immune checkpoint inhibitors(ICI)is immune-related adverse events(IrAEs)ranging from low grade toxicities to life-threatening end organ damage requiring permanent discontinuation of *** are reported in300 was significantly associated with a lower incidence of grade≥2 IrAEs(OR=0.40;P=0.044).Similarly,a trend was observed between NLR>5 and lower incidence of grade≥2 IrAEs(OR=0.58;P=0.097).Multivariate analyses confirmed PLR>300 as an independent predictive marker of grade≥2 IrAEs(OR=0.26;P=0.011),in addition to treatment with programmed cell death ligand 1(PD-1)/cytotoxic T lymphocyte-associated protein-4(OR=2.57;P=0.037)and PD-1/tyrosine kinase inhibitor(OR=3.39;P=0.01)*** use was not associated with IrAE incidence(OR=1.02;P=0.954).Patients treated with steroids had a>2-fold higher incidence of gr

关键词： Neutrophil-lymphocyte ratio Platelet-lymphocyte ratio Inflammatory biomarkers Immunotherapy Immune toxicity

High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2021年第24期27卷 3630-3642页

作者： Ulrike Bauer Sabine Gerum Falk Roeder Stefan Münch Stephanie E Combs Alexander B Philipp Enrico N De Toni Martha M Kirstein arndt vogel Carolin Mogler Bernhard Haller Jens Neumann Rickmer F Braren Marcus R Makowski Philipp Paprottka Markus Guba Fabian Geisler Roland M Schmid Andreas Umgelter Ursula Ehmer Internal Medicine Ⅱ Klinikum rechts der IsarTechnical University of MunichMunich 81675Germany Department of Radiotherapy and Radiation Oncology University of SalzburgSalzburg 5020Austria Department of Radiation Oncology University Hospital of MunichCampus GroßhadernLMU MunichMunich 81377Germany Department of Radiation Oncology Klinikum rechts der IsarTechnical University of MunichMunich 81675Germany Department of Medicine II Liver CentreUniversity HospitalLMU MunichMunich 81377Germany Department of Gastroenterology Hepatology and EndocrinologyHannover Medical SchoolHannover 30625Germany Institute of Pathology Technical University of MunichMunich 81675Germany Institute of Medical Informatics Statistics and EpidemiologyKlinikum rechts der IsarTechnical University of MunichMunich 81675Germany Institute of Pathology Faculty of MedicineUniversity Hospital of MunichMunich 81377Germany Institute of Diagnostic and Interventional Radiology Klinikum rechts der IsarTechnical University of MunichMunich 81675Germany Institute of Diagnostic and Interventional Radiology Section for Interventional RadiologyKlinikum rechts der IsarTechnical University of MunichMunich 81675Germany Department of General- Visceral-Vascular-and Transplant-SurgeryUniversity hospital of MunichCampus GroßhadernLMU MunichMunich 81377Germany Emergency Department Vivantes hospital groupHumboldt hospitalBerlin 13509Germany

BACKGROUND Liver transplantation(LT)presents a curative treatment option in patients with early stage hepatocellular carcinoma(HCC)who are not eligible for resection or ablation *** to a risk of up 30%for waitlist drop-out upon tumor progression,bridging therapies are used to halt tumor *** chemoembolization(TACE)and less commonly stereotactic body radiation therapy(SBRT)or a combination of TACE and SBRT,are used as bridging therapies in ***,it remains unclear if one of those treatment options is *** analysis of explant livers after transplantation provides the unique opportunity to investigate treatment response by *** To analyze histopathological response to a combination of TACE and SBRT in HCC in comparison to TACE or SBRT *** In this multicenter retrospective study,27 patients who received liver transplantation for HCC were *** received either TACE or SBRT alone,or a combination of TACE and SBRT as bridging therapy to liver *** explants of all patients who received at least one TACE and/or SBRT were analyzed for the presence of residual vital tumor tissue by histopathology to assess differences in treatment response to bridging *** analysis was performed using Fisher-Freeman-Halton exact test,Kruskal-Wallis and Mann-Whitney-U *** Fourteen patients received TACE only,four patients SBRT only,and nine patients a combination therapy of TACE and *** were no significant differences between groups regarding age,sex,etiology of underlying liver disease or number and size of tumor ***,analysis of liver explants revealed that almost all patients in the TACE and SBRT combination group(8/9,89%)showed no residual vital tumor tissue by histopathology,whereas TACE or SBRT alone resulted in significantly lower rates of complete histopathological response(0/14,0%and 1/4,25%,respectively,P value<0.001).CONCLUSION Our data suggests th

关键词： Hepatocellular carcinoma Transarterial chemoembolization Stereotactic body radiation therapy Bridging therapy Liver transplantation